Trust Company’s Vaxcyte PCVX Stock Holding History

Trust Company’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$581	Hold	10	–	–	﹤0.01%	712
2026 Q1	$581	Hold	10	–	–	﹤0.01%	672
2025 Q4	$461	Buy	+10	New	+$447	﹤0.01%	719

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Trust Company's PCVX Position: Q2 2026 in Review

Trust Company held its Vaxcyte (PCVX) position steady in Q2 2026 at 10 shares worth $581. The position accounts for ﹤0.01% of the portfolio, ranked #712.

Trust Company first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Trust Company held 10 shares of Vaxcyte worth $581 as of Q2 2026.
Trust Company left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up ﹤0.01% of Trust Company's portfolio in Q2 2026, its #712 holding.
Trust Company first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.